RENOVORX INC
RNXTNASDAQTrading Snapshot
- Day Range
- $0.94 โ $1.03
- 52-Week Range
- $0.73 โ $2.59
- Volume (shares)
- 477,430
- Avg Volume (shares)
- โ
- Shares Outstanding
- 45.1M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $1M
- P/E Ratio
- โ
- P/S Ratio
- 23.0x
- EPS (TTM)
- $-0.31
- Dividend Yield
- โ
- Dilution (1yr)
- +58.6%
RENOVORX INC
RNXTAbout RENOVORX INC
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors
MOUNTAIN VIEW, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (โRenovoRxโ or โthe Companyโ) (Nasdaq: RNXT), a life sciences company commercializing RenovoCath ยฎ , a patented, FDA-cleared drug-delivery device, a

RenovoRx Q3 Earnings Call Highlights
RenovoRx NASDAQ: RNXT reported record third-quarter 2026 revenue of $1.07 million, exceeding $1 million in quarterly sales for the first time as more cancer centers adopted its RenovoCath drug-delivery device.

RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript
RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion Using TAMP B

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ย (โRenovoRxโ or โthe Companyโ) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoC